

Please amend the application as follows:

IN THE CLAIMS

Please cancel claim 27.

REMARKS

No change in inventorship under 37 CFR 1.48(b) is merited by cancellation of claim 27 under 37 CFR 1.121 and as such, no request under 37CFR 1.48(b) or fee under 37 CFR 1.17(i) are submitted. The response to the Restriction Requirement is due on or before November 4, 2002. No new matter is added herein. The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-1169. An early action on the merits is kindly requested. Applicants respectfully submit that the pending claims are in a condition for allowance. The undersigned can be reached at 408-746-4536 if the Examiner wishes to discuss the response.

Respectfully submitted,

Date: November 1, 2002

By: Malabika J. Ghosh
Malabika J. Ghosh
Agent for Applicants
Registration No: P -52,476

Luisa Bigornia
Attorney for Applicants
Registration No.: 45,974
HYSEQ, INC.
670 Almanor Avenue
Sunnyvale, CA 94085
(408) 524-8100
(408) 524-8145 (Telefacsimile)

Version With Markings to Show Changes

IN THE CLAIMS:

Please cancel claim 27.

27. (New) A method of detecting the presence of a CD39L2 polypeptide having the amino acid sequence of SEQ ID NO. 2 or a fragment thereof in a cell, tissue or fluid sample comprising

contacting said cell, tissue or fluid sample with an antibody or fragment of claim 19 under conditions which permit the formation of an antibody/polypeptide complex and

detecting the presence of an antibody/polypeptide complex, wherein the presence of the antibody/polypeptide complex indicates the presence of a CD39L2 polypeptide.